Merck has reached a nearly $6 billion cash deal to buy the cancer biotech Terns Pharmaceuticals and its promising leukemia treatment

2 months ago 46

The drugmaker has been seeking to bolster its pipeline arsenic its top-selling drug, Keytruda, is acceptable to suffer patent protection.